Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease

BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality in patients with nonalcoholic fatty liver disease (NAFLD). Weight loss is a key factor for successful NAFLD and CVD therapy. Ursodeoxycholic acid (UDCA), which is one of the first-line therapeutic agents for...

Descripción completa

Detalles Bibliográficos
Autores principales: Nadinskaia, Maria, Maevskaya, Marina, Ivashkin, Vladimir, Kodzoeva, Khava, Pirogova, Irina, Chesnokov, Evgeny, Nersesov, Alexander, Kaibullayeva, Jamilya, Konysbekova, Akzhan, Raissova, Aigul, Khamrabaeva, Feruza, Zueva, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Clinical Trials Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7968130/
https://www.ncbi.nlm.nih.gov/pubmed/33776366
http://dx.doi.org/10.3748/wjg.v27.i10.959

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7968130/
https://www.ncbi.nlm.nih.gov/pubmed/33776366
http://dx.doi.org/10.3748/wjg.v27.i10.959

Ejemplares similares